{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=10", "query": { "condition": "Genetic Change", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 1794, "total_pages": 180, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T15:38:17.163Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06119581", "title": "A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Neoplasm Metastasis" ], "interventions": [ { "name": "LY3537982", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1264, "start_date": "2023-12-21", "completion_date": "2031-01", "has_results": false, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-11T15:38:17.163Z", "location_count": 87, "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 72 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06119581" }, { "nct_id": "NCT04439292", "title": "Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Hematopoietic and Lymphoid Cell Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Dabrafenib Mesylate", "type": "DRUG" }, { "name": "Trametinib Dimethyl Sulfoxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2016-01-04", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-11-11T15:38:17.163Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04439292" }, { "nct_id": "NCT07304011", "title": "Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Olutasidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2025-12-17", "completion_date": "2029-12-01", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-11-11T15:38:17.163Z", "location_count": 2, "location_summary": "Orange, California • Sacramento, California", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07304011" }, { "nct_id": "NCT06607185", "title": "A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Non-small Cell Lung Cancer", "Colorectal Cancer", "Advanced Solid Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "LY4066434.", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "5Fluorouracil", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 750, "start_date": "2024-10-21", "completion_date": "2030-01", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-11-11T15:38:17.163Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06607185" }, { "nct_id": "NCT00700778", "title": "Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "BRCA1 Mutation", "Breast Cancer" ], "interventions": [ { "name": "recombinant human chorionic gonadotropin", "type": "BIOLOGICAL" }, { "name": "microarray analysis", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "needle biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "20 Years to 40 Years · Female only" }, "enrollment_count": 2, "start_date": "2008-07", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2021-01-25", "last_synced_at": "2026-11-11T15:38:17.163Z", "location_count": 2, "location_summary": "Rochester, Minnesota • Philadelphia, Pennsylvania", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00700778" }, { "nct_id": "NCT00001643", "title": "Gene Analysis of Parkinson's Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Parkinson's Disease" ], "interventions": [], "intervention_types": [], "sponsor": "National Human Genome Research Institute (NHGRI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "1997-08-29", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-11-11T15:38:17.163Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001643" }, { "nct_id": "NCT03644355", "title": "Asthma and Obesity Diet Versus Exercise", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity, Childhood", "Asthma in Children", "Inflammatory Response", "Metabolic Syndrome", "Nutrition Poor", "Physical Activity", "Behavior, Eating", "Molecular Biology, Restriction Fragment Length Polymorphisms", "Maternal Exposure", "Genetic Change" ], "interventions": [ { "name": "Lifestyle counseling", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Louisiana State University Health Sciences Center in New Orleans", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "13 Years", "maximum_age": "19 Years", "sex": "FEMALE", "summary": "13 Years to 19 Years · Female only" }, "enrollment_count": 110, "start_date": "2010-05-19", "completion_date": "2016-08-04", "has_results": false, "last_update_posted_date": "2018-08-23", "last_synced_at": "2026-11-11T15:38:17.163Z", "location_count": 1, "location_summary": "New Orleans, Louisiana", "locations": [ { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03644355" }, { "nct_id": "NCT04955938", "title": "A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "IDH Mutation", "IDH1 Mutation", "IDH2 Gene Mutation", "Blood Cancer", "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Ivosidenib", "type": "DRUG" }, { "name": "Enasidenib", "type": "DRUG" }, { "name": "Fedratinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-10-29", "completion_date": "2023-06-07", "has_results": false, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-11-11T15:38:17.163Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04955938" }, { "nct_id": "NCT03658135", "title": "BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Tauopathies", "Corticobasal Degeneration Syndrome", "Frontotemporal Lobar Degeneration With Tau Inclusions", "MAPT Mutation Carriers, Symptomatic", "Traumatic Encephalopathy Syndrome", "Nonfluent Aphasia, Progressive" ], "interventions": [ { "name": "BIIB092", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "35 Years to 80 Years" }, "enrollment_count": 22, "start_date": "2018-09-12", "completion_date": "2019-12-13", "has_results": false, "last_update_posted_date": "2019-12-19", "last_synced_at": "2026-11-11T15:38:17.163Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03658135" }, { "nct_id": "NCT02704858", "title": "Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "Perillyl alcohol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neonc Technologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2017-08-01", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-11-11T15:38:17.163Z", "location_count": 11, "location_summary": "Los Angeles, California • San Francisco, California • Santa Monica, California + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02704858" } ] }